Mitsubishi UFJ Trust & Banking’s Kymera Therapeutics KYMR Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$158K	Buy	+1,376	New	+$118K	﹤0.01%	1389

Other funds holding KYMR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's KYMR Position: Q2 2026 in Review

Mitsubishi UFJ Trust & Banking opened a new position in Kymera Therapeutics (KYMR) in Q2 2026: 1,376 shares worth $158K. The stake represents ﹤0.01% of the portfolio and ranks #1389 among its holdings.

93 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

Mitsubishi UFJ Trust & Banking held 1,376 shares of Kymera Therapeutics worth $158K as of Q2 2026.
Kymera Therapeutics was a new Mitsubishi UFJ Trust & Banking position in Q2 2026.
Kymera Therapeutics made up ﹤0.01% of Mitsubishi UFJ Trust & Banking's portfolio in Q2 2026, its #1389 holding.
93 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q2 2026, filed 6 Aug 2026.